XTL Biopharmaceuticals Ltd is engaged in the field of healthcare. It is a pharmaceutical manufacturer, with a focus on acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
XTLB has seen a decrease in short interest as of late.
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the recipient of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 12,800 shares, a decline of 14.1% from the September 30th total of 14,900 shares. Based on an average trading volume of 17,200 shares, the short-interest ratio is currently 0.7 days.
HPNswingtrades 